Stocks in the health-care industry rose as markets grew more confident that U.S. borrowing costs will fall, while companies in the sector pleased investors in their quarterly reports. Gilead Sciences ...

The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

GSK is set to receive up to $500 million and 1% royalties on future vaccine sales following the settlement of a US patent dispute between CureVac NV, Pfizer, and BioNTech SE.

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Unlike other vaccines, mRNA vaccines can be made very quickly. They can also be easily modified to fight new viruses and ...

GSK said it will receive $370 million as part of the U.S. patent settlement involving CureVac and BioNTech over mRNA-based COVID-19 vaccines, The Wall Street Journal reported Aug. 8. Under the deal, ...

Shares of behavioral health company LifeStance Health (NASDAQ:LFST) jumped 11% in the afternoon session after the company ...

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain s GSK and Germany s CureVac $740 ...

U.S. Clinical Nutrition Market Growth BURLINGAME, CA, UNITED STATES, August 8, 2025 /EINPresswire / -- Latest Report, titled U.S ...

Donald Trump’s tariffs have dragged markets on a merry dance for much of this year. Goods being shipped into the US are now subject to levies of up to 39 per cent and a new front targeting ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...